KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|New England Journal of Medicine|2020Cited by 1.9k
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Journal of Clinical Oncology|2022Cited by 331
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal Shah, William G. Wierda, Michael R. Bishop et al.|Blood|2021Cited by 204
End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).Bijal Shah, William G. Wierda, Michael Bishop et al.|Journal of Clinical Oncology|2019Cited by 38
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Blood|2019Cited by 23